PMID- 33946817
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210527
IS  - 2076-0817 (Print)
IS  - 2076-0817 (Electronic)
IS  - 2076-0817 (Linking)
VI  - 10
IP  - 5
DP  - 2021 Apr 29
TI  - Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative 
      Colitis Despite a Negative Quantiferon Test.
LID - 10.3390/pathogens10050535 [doi]
LID - 535
AB  - Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is 
      commonly used to treat inflammatory bowel disease (IBD) and other autoimmune 
      disorders. However, it is known to increase the risk of reactivation of latent 
      tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a 
      case of extrapulmonary TB in a patient with ulcerative colitis who was treated 
      with Infliximab after a negative Quantiferon Test. In addition, we report briefly 
      on the current controversy about the appropriateness, interval, and methods for 
      the repeated screening of latent TB in IBD patients that are treated with 
      antitumor necrosis factor alpha (TNF-alpha) antibodies.
FAU - Colombo, Anna
AU  - Colombo A
AD  - Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - Giuffre, Mauro
AU  - Giuffre M
AUID- ORCID: 0000-0002-9910-3514
AD  - Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - Croce, Lory Saveria
AU  - Croce LS
AUID- ORCID: 0000-0001-9890-7011
AD  - Department of Medicine, Surgery and Health Sciences, University of Trieste, 34149 
      Trieste, Italy.
FAU - Venturini, Sergio
AU  - Venturini S
AUID- ORCID: 0000-0003-0271-0826
AD  - Department of Infectious Diseases, Azienda Sanitaria Friuli Occidentale, 
      Pordenone Hospital, 33170 Pordenone, Italy.
FAU - Sablich, Renato
AU  - Sablich R
AD  - IBD Unit, Department of Gastroenterology, Azienda Sanitaria Friuli Occidentale, 
      Pordenone Hospital, 33170 Pordenone, Italy.
LA  - eng
PT  - Case Reports
DEP - 20210429
PL  - Switzerland
TA  - Pathogens
JT  - Pathogens (Basel, Switzerland)
JID - 101596317
PMC - PMC8145928
OTO - NOTNLM
OT  - Infliximab
OT  - Quantiferon
OT  - inflammatory bowel disease
OT  - peritoneal tuberculosis
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/06 06:00
MHDA- 2021/05/06 06:01
PMCR- 2021/04/29
CRDT- 2021/05/05 01:02
PHST- 2021/02/09 00:00 [received]
PHST- 2021/04/21 00:00 [revised]
PHST- 2021/04/26 00:00 [accepted]
PHST- 2021/05/05 01:02 [entrez]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2021/05/06 06:01 [medline]
PHST- 2021/04/29 00:00 [pmc-release]
AID - pathogens10050535 [pii]
AID - pathogens-10-00535 [pii]
AID - 10.3390/pathogens10050535 [doi]
PST - epublish
SO  - Pathogens. 2021 Apr 29;10(5):535. doi: 10.3390/pathogens10050535.